Complete Remission of Relapsed Hodgkin’s Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report

Purwanto, Ibnu; Utomo, Bambang Purwanto; Ghozali, Ahmad

doi:10.1159/000505830

Cited by 5 publications

(10 citation statements)

References 8 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data may be valuable because to our knowledge, there have been no previous reports showing the pathological findings or evaluation of foci that have achieved remission status with chemotherapy for HL. There have been reports of cases of recurrent HL controlled with intense chemotherapy, confirmed by FDG‐PET/CT 7 . The usefulness of biomarkers, such as thymus and activation‐regulated chemokine as prognostic and treatment monitoring for HL has also been reported 8,9 .…”

Section: Discussionmentioning

confidence: 96%

A case of complete remission of Hodgkin lymphoma confirmed histopathologically by neck dissection

et al. 2023

View full text Add to dashboard Cite

BackgroundHodgkin lymphoma (HL) is diagnosed definitively by biopsy, and treatment is based on stage. Owing to the nature of the disease, post‐treatment efficacy is determined mainly by fluorodeoxyglucose‐positron emission tomography/computed tomography, and the efficacy of treatment is not confirmed by histopathology. We report a case of tongue cancer after treatment for HL, in which a post‐treatment lymph node with complete remission was histopathologically confirmed by neck dissection.CaseThe patient was a 74‐year‐old man who was referred to our hospital for cancer on the right side of his tongue. He had previously undergone chemotherapy for HL involving the right side of his neck and achieved complete remission. Because he had cT3N2cM0 tongue cancer, glossectomy and bilateral neck dissection were performed. Surprisingly, histopathological examination revealed that there was neither metastatic lymph nodes nor lymphoma cells in his right neck. Moreover, there was no lymphatic structure in his remnant lymph nodes.ConclusionThis was a rare case in which complete remission of HL was confirmed by histopathological analysis. The absence of lymph node structure and lymphatic flow led to contralateral neck lymph node metastases of tongue cancer.

show abstract

Section: Discussionmentioning

confidence: 96%

A case of complete remission of Hodgkin lymphoma confirmed histopathologically by neck dissection

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For instance, the combination of gemcitabine with Brentuximab vedotin has been shown to produce positive outcomes in other hematological malignancies. 20 1.8 mg/kg. Within the first four cycles of therapy 24 (57%) patients had a complete response with a tolerable toxicity profile.…”

Section: Discussionmentioning

confidence: 98%

“…For instance, the combination of gemcitabine with Brentuximab vedotin has been shown to produce positive outcomes in other hematological malignancies 20 . Cole et al demonstrated the safety and efficacy of gemcitabine in association with brentuximab vedotin in 42 patients with refractory Hodgkin's lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Continuous low‐dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study

Raimondo

Vaccarini

Nunzi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

The aim of our retrospective study was to evaluate the efficacy of a continuous therapy with a lower dosage of gemcitabine compared to those usually administered in patients with cutaneous T cell lymphomas (CTCL). Twenty‐two patients received different dosages of gemcitabine. Dosage and schedule of the drug were chosen on the basis of clinical features. Gemcitabine was given at 1000 mg every 15 days in 13 patients (four mycosis fungoides [MF], nine Sezary syndrome [SS]); at 1000 mg at days +1, +8, +15 in six cases (three MF, three SS). All patients had been previously treated: four patients had received both skin directed and systemic treatments. Eighteen patients had received photopheresis, IFN, chemotherapy and immunotherapy. The objective response rate (CR + PR) among all patients was 54.5% (12 of 22 patients) with a CR of 4.5% (one of 22 patients) and a PR of 50% (11 of 22 patients). Patients with SS had an ORR of 61.5% (eight of 13 patients) with one CR (7%) and seven PR (53.8%); patients with MF showed an ORR of 55.6% (five of nine patients) but no patients experienced CR (0%). The schedule with the highest efficacy and the lowest toxicity profile was 1000 mg every 15 days. Median progression free survival and overall survival in all patients were 17 and 45 months respectively. Gemcitabine was generally well tolerated. We have demonstrated that a much lower dose of gemcitabine (1000 mg once every 15 days) in patients with advanced‐stage and refractory CTCL can lead to a durable response, with tolerable and manageable adverse effects.

show abstract

“…10 Symptom presentation occurred 2 to 3 days after intravenous gemcitabine administration. 3,4 Two other cases took 6 to 10 days to manifest, so the patients underwent exhaustive workups to arrive at gemcitabine-induced SCLS as a diagnosis of exclusion. 5,7 In all the cases, the symptoms resolved after treatment with intravascular volume repletion, corticosteroids, diuretics, and occasionally vasopressors.…”

Section: Discussionmentioning

confidence: 99%

“…2 Gemcitabine's intravenous use has been associated with several side effects including systemic capillary leak syndrome (SCLS), a rare disorder with a high mortality rate thought to arise from endothelial damage and characterized by rapid-onset edema, hypotension, hemoconcentration, and hypoproteinemia. Although scattered case reports of gemcitabine-induced SCLS have been described, [2][3][4] there are no reports of SCLS after intravesical gemcitabine administration. We describe a case of postoperative vasoplegia associated with intravesical gemcitabine suspected to be SCLS.…”

Section: Persistent Postoperative Vasoplegia After Ureteronephrectomy...mentioning

confidence: 99%

Persistent Postoperative Vasoplegia After Ureteronephrectomy Due To Suspected Intravesical Gemcitabine Toxicity

2021

View full text Add to dashboard Cite

We describe a case of unusually persistent vasoplegia in the postoperative course of a patient recovering after elective right robotic nephroureterectomy with intravesical salvage gemcitabine. In the treatment of patients with intravesical adjuvant therapy, gemcitabine may precipitate persistent vasoplegia requiring further fluid resuscitative efforts, vasopressor support, and other supportive management. This potential adverse event should be considered when all common causes of persistent vasoplegia are ruled out, such as shock related to bleeding, infection, allergic reaction, or pulmonary embolic phenomenon.

show abstract

Complete Remission of Relapsed Hodgkin’s Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report

Cited by 5 publications

References 8 publications

A case of complete remission of Hodgkin lymphoma confirmed histopathologically by neck dissection

A case of complete remission of Hodgkin lymphoma confirmed histopathologically by neck dissection

Continuous low‐dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study

Persistent Postoperative Vasoplegia After Ureteronephrectomy Due To Suspected Intravesical Gemcitabine Toxicity

Contact Info

Product

Resources

About